Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimis study: Biofermin (Bifidobacterium) for IBS-like symptoms in remission Crohn's disease
jRCTs031200327Completed
- Sponsor
- Biofermin Pharmaceutical
- Start
- Mar 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Golden Bifid in Crohn's disease, sponsored by Biofermin Pharmaceutical. Primary endpoint: Change in fecal calprotectin. Started Mar 2021; status: completed.
02
Drugs
Golden Bifid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCTs031200327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200327.